Redundancies, restructures and tighter headcounts have triggered a shift away from traditional linear career progression with most new jobs in industry now a "sideways move" rather than a promotion
Senior leader named as Director of Policy and External Engagement just as the industry body heads into crucial Strategic Agreement negotiations
Pharma confirms its decision to discontinue a long-standing cancer drug from the Australian market on the same day as its anaemia therapy
On the 7.30 Report this week Dave Ricks made it clear he was not interested in accepting a low-ball price to have the company's blockbuster drug listed on the PBS
Doctors have lifted the lid on what they really want when it comes to medical information, with non-pharma companies ready to disrupt industry's relationship with HCPs
On a sabbatical year, this well-known industry executive has entered the Australian Portrait Artist of the Year Competition, painting Dannii Minogue
A researcher has won the AAMRI RIsing Star Award, sponsored by CSL, for her groundbreaking research into gut immunity and inflammatory disease
Who's nabbed the former Health Minister as a Non-Executive Director to advise on medicines policy and support the company's next phase of growth?
With this company ready to accelerate growth, a successful entrepreneur known across industry takes on Chair role after an oversubscribed seed funding round
This company has been ordered to face trial over allegations it defrauded investors by withholding information about a clinical trial for a next-gen drug
A rapid review will be held into MS drugs to see whether PBAC processes compare them appropriately when recommending cost-minimised listings
The Aussie giant said it stands behind the science of the new technology but changes to the regulatory regime in the US has made the broader market less attractive
With 10 prescription medicine applications on the TGA's review list, this pharma is at the forefront of bringing new therapies to Australia
Strong growth for some drugs, sharp falls and lost exclusivity for others means the Top 10 PBS Earners list now looks very different than it did a year ago
